RxDoctor Payments Data

Nadia Gaddi, MD

Family Medicine · Houston, TXNPI 1336375013

Payments from drug & device makers

$1,756in general payments, 2019–2025

Across 98 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$353
  • AstraZeneca$266
  • Boehringer Ingelheim$248
  • Lilly USA, LLC$222
  • Amgen$204
  • Sanofi-aventis U.S. LLC$93
  • plus $370 from 9 others

What the payments were for

  • Food & beverage$1,69697%
  • Gifts$593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,756 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$33,785
Medicare patients
55
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$83,491
JardianceEmpagliflozin53$57,527
TrulicityDulaglutide37$37,754
JanuviaSitagliptin Phosphate23$37,138
FarxigaDapagliflozin Propanediol27$26,517
MounjaroTirzepatide22$23,263
Tresiba Flextouch U-100Insulin Degludec22$10,580
Combivent RespimatIpratropium/Albuterol Sulfate18$9,219
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,001
MyrbetriqMirabegron13$5,996
Rosuvastatin Calcium126$3,442
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,121
Famotidine102$1,622
Atorvastatin Calcium193$1,528
Ibandronate Sodium36$1,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$353$83,49172 claims
Boehringer IngelheimJardiance, Combivent Respimat$248$66,74571 claims
Lilly USA, LLCTrulicity, Mounjaro$222$61,01759 claims
AstraZenecaFarxiga$266$26,51727 claims
GSKTrelegy Ellipta$18$7,00111 claims
Astellas Pharma US IncMyrbetriq$55$5,99613 claims
AbbVieSynthroid$17$1,40919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →